Competing biotechs swarm to develop gene-editing treatments for alpha-1 antitrypsin deficiency
Multiple companies are pursuing CRISPR and gene-editing approaches for AATD, a rare inherited lung and liver disease, amid patent disputes, a start-up exodus, and US–China competitive tensions reported by Stat News.
A Stat News feature published on 28 July 2026 describes a rapidly expanding commercial and scientific competition to develop curative treatments for alpha-1 antitrypsin deficiency (AATD), a rare autosomal recessive condition caused by pathogenic variants in the SERPINA1 gene. AATD results in misfolded protein accumulating in hepatocytes and reduced circulating alpha-1 antitrypsin, which normally protects lung tissue from neutrophil elastase-driven damage; affected individuals are at elevated risk of emphysema and liver disease.
The field, long considered underfunded relative to its disease burden, has attracted a cluster of biotechnology companies deploying CRISPR base editing, prime editing, and RNA-based strategies. The Stat News report documents patent disputes between competing programmes, defections of researchers between start-ups, and an international dimension involving US and Chinese companies working on overlapping approaches.
AATD is a condition of direct relevance to genetic counsellors and clinical geneticists because carrier frequency is relatively high in populations of Northern European ancestry, and family-based genetic testing is established practice. Researchers in gene therapy and genome editing will recognise the SERPINA1 locus as a technically demanding target owing to the dominant-negative nature of the Z allele and the liver's role as the primary site of production.
The Stat News piece is a reported feature, not a primary research publication, and does not announce any regulatory approvals or changes to published clinical management guidelines for AATD.
Plain-language version
For patients, families, and general readers. Educational only — not medical advice.
Alpha-1 antitrypsin deficiency (AATD) is an inherited condition that can cause serious lung and liver problems. It is caused by changes in both copies of a gene called SERPINA1 that people inherit from their parents. For a long time, treatment options have been limited, but researchers now describe AATD as an area attracting a lot of attention and investment from biotech companies — sometimes called a "gold rush" — because new gene-editing technologies may one day offer a way to correct the underlying genetic fault.
A news report from Stat News describes several companies competing to develop these treatments, and mentions disagreements over patents and scientific priority. No new treatment has been approved as a result of this activity; the report reflects the state of research and development, not a finished medicine.
This is an educational summary, not medical advice. If anything here raises questions for you, please speak with your GP or a clinical professional.
Sources
Read the original reporting — these are the public sources this summary draws from.
-
Primary source Stat News · 2026-07-28From 'lost cause' to gold rush: Biotechs swarm to cure AATD